preclinical model raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | lyophilized form |
| Typical purity | 95 percent or higher by RP-HPLC | value depends on method |
| Storage temperature | minus 20 degrees Celsius or below | desiccated, protected from light |
| Reconstitution solvent | bacteriostatic water | sterile saline also used |
| Primary assay | RP-HPLC with UV detection | often paired with mass spectrometry |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
The company was founded in Pittsburgh, Pennsylvania, in 1902 by Chester Garfield Fisher (1881–1965), originally called the "Scientific Materials Co.". After obtaining his degree in engineering at Western University of Pennsylvania (now University of Pittsburgh), C.G. Fisher purchased the stockroom of the Pittsburgh Testing Laboratory. Fisher became a supplier of lab equipment and reagents for the area's industrial research. Early products included microscopes, burets, pipettes, litmus, balances, colorimeters, dissecting kits, and anatomical models. The first catalog, the 400 page Scientific Materials Co. Catalog of Laboratory Apparatus & Supplies, was published in 1904. Fisher established an R&D lab at his company in 1915. Edwin Fisher, Chester's brother, developed the Meker-Fisher burner in 1921, an advancement on the design of the Bunsen burner. The company manufactured an electric-combustion furnace and combustion train for analyzing carbon levels in steel, and an electrically heated and thermostatically controlled bacteriological incubator. In 1925, the company purchased Montreal-based Scientific Supplies, Ltd. The same year, the company was renamed Fisher Scientific. In 1940, Fisher Scientific acquired the New York supply company Eimer & Amend, which was founded in 1851 by Bernard G. Amend. Aiken Fisher, Chester's oldest son, became president of the company in 1949. In 1955, Fisher established a chemical manufacturing facility in Fair Lawn, New Jersey. In 1957, the company purchased the New York–based medical apparatus supply company E. Machlett & Sons.
RCO2H + R'OH ⇌ RCO2R' + H2O The equilibrium constant for such reactions is about 5 for typical esters, e.g., ethyl acetate. The reaction is slow in the absence of a catalyst. Sulfuric acid is a typical catalyst for this reaction. Many other acids are also used such as polymeric sulfonic acids. Since esterification is highly reversible, the yield of the ester can be improved using Le Chatelier's principle:
The interaction between fibronectin and the integrin receptor causes a conformational change in the fibronectin. Additional receptors bind to fibronectin bringing in type I collagen, procollagen I and collagen V. These molecules interact with fibronectin to promote fibril formation on the surface of the cell.
== Location == Keloids can develop in any place where skin trauma has occurred. They can be the result of pimples, insect bites, scratching, burns, or other skin injuries. Keloid scars can develop after surgery. They are more common in some sites, such as the central chest (from a sternotomy), the back and shoulders (usually resulting from acne), and the ear lobes (from ear piercings). They can also occur on body piercings. The most common spots are the earlobes, arms, pelvic region, and over the collarbone.
All isotopes ranging from 242Cm to 248Cm, as well as 250Cm, undergo a self-sustaining nuclear chain reaction and thus in principle can be a nuclear fuel in a reactor. As in most transuranic elements, nuclear fission cross section is especially high for the odd-mass curium isotopes 243Cm, 245Cm and 247Cm. These can be used in thermal-neutron reactors, whereas a mixture of curium isotopes is only suitable for fast breeder reactors since the even-mass isotopes are not fissile in a thermal reactor and accumulate as burn-up increases. The mixed-oxide (MOX) fuel, which is to be used in power reactors, should contain little or no curium because neutron activation of 248Cm will create californium. Californium is a strong neutron emitter, and would pollute the back end of the fuel cycle and increase the dose to reactor personnel. Hence, if minor actinides are to be used as fuel in a thermal neutron reactor, the curium should be excluded from the fuel or placed in special fuel rods where it is the only actinide present.
Sources: en.wikipedia.org
=== Lawsuits === In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon. Matthew Dougherty, a 51‑year‑old former teacher and artist with a diagnosis of schizophrenia, died on May 21, 2024, at Phoenixville Hospital in Phoenixville, Pennsylvania. According to a wrongful death lawsuit filed by his family in March 2025, Dougherty had been admitted to the hospital after a mental health crisis during which he was tased by police and suffered injuries. While hospitalized, Dougherty's regular psychiatric medications were discontinued. On the evening of his death, an alarm sounded in a nearby room, causing him to become agitated. Hospital staff called the police to restrain him, and responding officers again used a taser on Dougherty. Shortly afterward, nurses administered two doses of Geodon (ziprasidone) – a total of 40 mg, an amount the lawsuit equated to "administering poison". Minutes later, Dougherty went into cardiac arrest and could not be resuscitated. The lawsuit names as defendants Tower Health, which operates Phoenixville Hospital, and seeks damages for wrongful death and negligence. At the time the suit was filed, Tower Health had not filed a response to the complaint.
Liu had seized the Chengdu Arsenal in 1925 after Yang Sen's downfall, but to appease the city's other warlords, he announced plans to convert it into a mechanical repair shop rather than a weapons factory. To oversee this process, he appointed his brother Liu Wencheng, who had previously run a distillery, as its manager. Liu Wencheng would also later be appointed to several managerial positions in industrial enterprises. The Chengdu Arsenal would eventually be converted into a mint, increasing Liu Wenhui's money supply. Liu's brother Wencheng used his position in Chengdu to purchase houses and land, expanding his family's real estate holdings. He purchased so much property that his rivals nicknamed him "Liu Half-City", implying he owned half of Chengdu. Liu Wenhui's army continued growing due to money and industrial supplies from his brothers. Over the course of 1926, he attacked and disarmed the forces of Yang Chunfang in January and Lü Chao in April, taking control of Lü's territories in southern Sichuan. To formalize the division of Chengdu, Liu, Deng, and Tian established a joint command in December 1926 with Liu as director. In December 1926, communist forces under Liu Bocheng launched the Luzhou Uprising in Sichuan as part of the Northern Expedition. Liu Bocheng's forces successfully took control of the city from warlord Lai Xinhui. Control of Luzhou was coveted by several neighboring warlords, who had also begun besieging the city. To prevent his rivals from capturing Luzhou, Liu dispatched his friend Leng Yingdong to surround the city in April 1927.
=== Altered platelet function === Congenital Disorders of adhesion Bernard–Soulier syndrome Disorders of activation Disorders of granule amount or release Hermansky–Pudlak syndrome Gray platelet syndrome ADP receptor defect Decreased cyclooxygenase activity Platelet storage pool deficiency Disorders of aggregation Glanzmann's thrombasthenia Wiskott–Aldrich syndrome Disorders of coagulant activity COAT platelet defect Scott syndrome Acquired Disorders of adhesion Paroxysmal nocturnal hemoglobinuria Asthma Aspirin-exacerbated respiratory disease (AERD/Samter's triad) Cancer Malaria Decreased cyclooxygenase activity
=== 1987 === January 1987 – Gorbachev introduces the policy of demokratizatsiya in the Soviet Union. January 27, 1987 – The United States recognizes the independence of Mongolia and establishes diplomatic relations. March 4, 1987 – In a televised address, Reagan takes full responsibility for the Iran–Contra affair. June 12, 1987 – "Tear down this wall" speech by Reagan in West Berlin. June 29, 1987 – June Struggle in South Korea. July 15, 1987 – The Republic of China ends 38 years of martial law. November 15, 1987 – Brașov rebellion in Romania. December 8, 1987 – The Intermediate-Range Nuclear Forces Treaty is signed in Washington, D.C.
==== Industrial applications ==== Many industrial processes rely on reactions using chemicals dissolved in water, suspension of solids in water slurries or using water to dissolve and extract substances, or to wash products or process equipment. Processes such as mining, chemical pulping, pulp bleaching, paper manufacturing, textile production, dyeing, printing, and cooling of power plants use large amounts of water, requiring a dedicated water source, and often cause significant water pollution. Water is used in power generation. Hydroelectricity is electricity obtained from hydropower. Hydroelectric power comes from water driving a water turbine connected to a generator. Hydroelectricity is a low-cost, non-polluting, renewable energy source. The energy is supplied by the motion of water. Typically a dam is constructed on a river, creating an artificial lake behind it. Water flowing out of the lake is forced through turbines that turn generators.
Sources: en.wikipedia.org
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.
Most suppliers state a purity of ninety-five percent or higher by reversed-phase chromatography. Values below that threshold indicate a larger proportion of related peptides. The reported figure depends on the detection wavelength, usually 214 nanometers for peptides.
Sealed vials kept cold and dry retain potency for years in many cases. Exposure to warmth or moisture accelerates degradation. A stated expiration date is a supplier estimate rather than a measured endpoint.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.